On August 24, CANSINOBIO declined 5.16% in regular trading, trading at HK$27.9/share, with turnover of HK$205 million. The stock continues to face selling pressure following a massive surge earlier in the week driven by Moderna's mRNA cancer vaccine Phase 3 clinical trial success.

On August 19, Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine, the first such trial to succeed globally. CANSINOBIO surged approximately 48.59% on August 20 as institutional research noted the company's development pathway and antigen design are broadly similar to Moderna's, with differentiation in its three-component lipid nanoparticle delivery system. The stock subsequently fell around 8% on August 21 as profit-taking emerged.

The company issued an abnormal trading announcement stating it has no undisclosed material information, confirming that the mRNA platform is one of its established technology platforms. CLSA noted the Moderna success represents a platform-level valuation re-rating event. The ongoing correction reflects technical selling pressure following the sharp short-term rally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)